Clinical trials: Panic Disorders
Panic Disorders
Study Comparing Venlafaxine vs. Paroxetine in Panic Disorder
The purpose of this pilot study is to evaluate the improvement in social function following therapy with venlafaxine extended release (XR) in the treatment of panic disorder (PD) in comparison to paroxetine.
- Trial name
- NCT00195598
- Testing
- VENLAFAXINE, Paroxetine
- Where
- 4 sites in Brazil
- Volunteers
- 70 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Panic Disorder
Study Evaluating Venlafaxine ER in Adults With Panic Disorder
The primary objective of this study is to determine the efficacy, safety, and tolerability of a flexible dose of venlafaxine extended-release (ER) capsules administered for 10 weeks in the treatment of adult outpatients with…
- Trial name
- NCT00038896
- Testing
- Venlafaxine ER
- Volunteers
- 343 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Panic Disorder
Study Evaluating Venlafaxine ER in Patients With Panic Disorder
The primary objective is to determine the efficacy, safety, and tolerability of venlafaxine extended release (ER) capsules in the treatment of outpatients with panic disorder (PD) in comparison to those of placebo.
- Trial name
- NCT00044772
- Testing
- Venlafaxine ER
- Volunteers
- 653 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Panic Disorder
ELB139 Given Orally to Patients With Concurrent Panic Disorder, Challenged by CO2 Inhalation After a Single Dose and One Week of Treatment
This study is designed to investigate if 600 mg ELB139 given orally t.i.d. to patients suffering from panic disorder is effective in reducing anxiety evoked by inhalation of 35% CO2 measured by a visual analogue scale after the…
- Trial name
- NCT00322803
- Testing
- ELB139
- Where
- 3 sites in Germany, Netherlands
- Volunteers
- 24 people
- Sponsor
- elbion AG